Latest Healthcare Research Reports

Tag: pain management

Facet-Joint Injection Market Forecast To Reach $4.1 Billion By 2030: Key Trends Explained

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Facet-Joint Injection Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The facet-joint injection market has seen robust expansion in recent years. It is projected to increase from $2.97 billion in 2025 to $3.18 billion in 2026, maintaining a compound annual growth rate (CAGR) of 6.9%. The market’s past growth is attributable to spinal degeneration prevalence, arthritis incidence, pain management awareness, corticosteroid use, and outpatient procedure growth.

The facet-joint injection market size is expected to experience robust growth over the next few years. It is forecast to reach $4.1 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This projected growth can be attributed to factors such as an aging population, a preference for minimally invasive treatments, the prevalence of chronic pain, the expansion of ambulatory care, and the use of imaging-guided procedures. Significant trends expected during the forecast period include a heightened demand for minimally invasive pain procedures, increased application in chronic back pain management, the proliferation of outpatient pain clinics, the adoption of image-guided injection techniques, and the growth of ambulatory surgical centers.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=89885468&type=smp&name=Facet-Joint%20Injection%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Facet-Joint Injection Market Growth Factors: What’s Supporting Expansion?

The increasing incidence of spinal conditions and persistent back pain is anticipated to fuel the expansion of the facet-joint injection market moving forward. Spinal diseases and chronic back pain encompass long-term ailments affecting the spine, such as disc degeneration, arthritis, or nerve compression, which result in ongoing discomfort, limited mobility, and a reduced quality of life. The growing prevalence of these conditions is attributed to sedentary lifestyles and poor posture, prompting individuals to seek effective, low-disruption treatments to alleviate persistent discomfort and restore functional movement. Facet-joint injections address spinal diseases and chronic back pain by diminishing pain and inflammation in the spine, offering relief to individuals suffering from the increasing issue of spinal diseases and chronic back pain. For instance, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, reported that in 2023, approximately 18,000 new spinal cord injury (SCI) cases are reported annually in the United States, with an estimated 302,000 individuals currently living with spinal cord injuries nationwide. Consequently, the rising occurrence of spinal diseases and chronic back pain is driving the growth of the facet-joint injection market. The expanding demand for minimally invasive procedures is expected to propel the growth of the facet-joint injection market in the coming years. Minimally invasive procedures are medical interventions performed through small incisions or without requiring extensive surgical cuts. The increasing adoption of minimally invasive procedures is due to a growing patient preference for quicker recovery times and reduced post-operative pain. Facet-joint injections enhance minimally invasive procedures by providing targeted pain relief and diagnostic accuracy without the necessity for major surgical intervention. For example, in 2023, the American Society of Plastic Surgeons, a US-based specialty organization, indicated that the total number of minimally invasive cosmetic procedures rose from 23.7 million in 2022 to 25.4 million in 2023. Therefore, the growing demand for minimally invasive procedures is driving the growth of the facet-joint injection market.

Facet-Joint Injection Market Segment Analysis And Revenue Potential

The facet-joint injection market covered in this report is segmented –

1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

Facet-Joint Injection Market Industry Trends: What’s Reshaping Demand?

Leading companies in the facet-joint injection market are concentrating on developing novel products, such as facet fusion systems, aimed at providing more prolonged relief and better treatment results. Facet fusion systems are medical devices specifically engineered to stabilize and fuse the spinal facet joints by encouraging bone growth connecting neighboring vertebrae. As an illustration, in March 2025, Aurora Spine Corporation, a medical device company situated in the US, revealed that the AEROTM Facet Fusion System, which is its latest product, obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system features an integrated titanium plasma spray coating designed to enhance osseointegration and its capacity for fusion. It supports a range of implant sizes to suit diverse patient anatomies and provides radiolucent instrumentation to improve visibility during surgical procedures. These attributes collectively strive to elevate procedural efficiency and the long-term effectiveness in addressing chronic back pain originating from facet joint disorders.

Facet-Joint Injection Market Key Players Shaping Industry Direction

Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

View The Full Facet-Joint Injection Market Report:

https://thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Facet-Joint Injection Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 20, 2026
Lumbosacral Radicular Pain Management Market Set To Expand From $1.17 Billion In 2026: Growth Outlook Through 2030

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Lumbosacral Radicular Pain Management Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The lumbosacral radicular pain management market has seen significant expansion over recent years. It is projected to expand from $0.9 billion in 2025 to $0.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to several factors including an increase in spinal disc disorders, the reliance on pharmacological methods for pain relief, the availability of hospital-based pain treatment, a rise in orthopedic consultations, and the development of physical therapy services.

The lumbosacral radicular pain management market size is anticipated to expand significantly over the next few years. It is projected to reach $1.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This growth during the forecast period is primarily driven by factors such as the expanding aging population, the increasing need for long-term pain management solutions, the adoption of non-invasive therapies, the growth of home-based rehabilitation services, and continuous advancements in pain diagnostics. Prominent trends for the forecast period encompass a growing inclination towards multimodal pain management approaches, a wider acceptance of non-opioid therapies, the expansion of interventions based on physical therapy, an increasing demand for minimally invasive pain treatments, and the integration of personalized pain management plans.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=94548638&type=smp&name=Lumbosacral%20Radicular%20Pain%20Management%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lumbosacral Radicular Pain Management Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The increasing occurrence of back pain conditions is projected to boost the expansion of the lumbosacral radicular pain management market in the future. Back pain disorders encompass various conditions impacting the spine, muscles, or nerves in the back, leading to discomfort or pain. The growing incidence of these disorders stems from sedentary lifestyles, which weaken back muscles, resulting in poor posture and chronic pain. Lumbosacral radicular pain management seeks to alleviate nerve root irritation in the lower back, thereby lessening pain and inflammation, while also restoring mobility and enhancing the quality of life. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, back problems were the third leading contributor to disease burden in Australia, representing 4.3% of the country’s total disease burden. Consequently, the increasing prevalence of back pain disorders fuels the growth of the lumbosacral radicular pain management market.

Lumbosacral Radicular Pain Management Market Segment Analysis And Revenue Potential

The lumbosacral radicular pain management market covered in this report is segmented –

1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

3) By Route Of Administration: Oral, Topical

4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

Lumbosacral Radicular Pain Management Market Innovation Trends Shaping Future Development

Companies operating within the lumbosacral radicular pain management market are concentrating on developing advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to provide a non-opioid alternative for prolonged pain relief. An investigational oral NaV1.8 pain signal inhibitor is an experimental drug targeting the NaV1.8 sodium channel, a key pathway for transmitting pain through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a US-based biotech company, announced the results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study met its primary endpoint, indicating a statistically significant and clinically meaningful reduction in pain from baseline within the suzetrigine group. Suzetrigine was generally well tolerated, with no serious adverse events reported. Vertex plans to address the significant placebo response in upcoming Phase 3 trials to better assess the drug’s efficacy.

Lumbosacral Radicular Pain Management Market Key Players Shaping Industry Direction

Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

View The Full Lumbosacral Radicular Pain Management Market Report:

https://thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lumbosacral Radicular Pain Management Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 13, 2026
Lumbosacral Radicular Pain Management Market Set To Expand From $1.17 Billion In 2026: Growth Outlook Through 2030

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Lumbosacral Radicular Pain Management Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The lumbosacral radicular pain management market has seen significant expansion over recent years. It is projected to expand from $0.9 billion in 2025 to $0.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to several factors including an increase in spinal disc disorders, the reliance on pharmacological methods for pain relief, the availability of hospital-based pain treatment, a rise in orthopedic consultations, and the development of physical therapy services.

The lumbosacral radicular pain management market size is anticipated to expand significantly over the next few years. It is projected to reach $1.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This growth during the forecast period is primarily driven by factors such as the expanding aging population, the increasing need for long-term pain management solutions, the adoption of non-invasive therapies, the growth of home-based rehabilitation services, and continuous advancements in pain diagnostics. Prominent trends for the forecast period encompass a growing inclination towards multimodal pain management approaches, a wider acceptance of non-opioid therapies, the expansion of interventions based on physical therapy, an increasing demand for minimally invasive pain treatments, and the integration of personalized pain management plans.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=94548638&type=smp&name=Lumbosacral%20Radicular%20Pain%20Management%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lumbosacral Radicular Pain Management Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The increasing occurrence of back pain conditions is projected to boost the expansion of the lumbosacral radicular pain management market in the future. Back pain disorders encompass various conditions impacting the spine, muscles, or nerves in the back, leading to discomfort or pain. The growing incidence of these disorders stems from sedentary lifestyles, which weaken back muscles, resulting in poor posture and chronic pain. Lumbosacral radicular pain management seeks to alleviate nerve root irritation in the lower back, thereby lessening pain and inflammation, while also restoring mobility and enhancing the quality of life. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, back problems were the third leading contributor to disease burden in Australia, representing 4.3% of the country’s total disease burden. Consequently, the increasing prevalence of back pain disorders fuels the growth of the lumbosacral radicular pain management market.

Lumbosacral Radicular Pain Management Market Segment Analysis And Revenue Potential

The lumbosacral radicular pain management market covered in this report is segmented –

1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

3) By Route Of Administration: Oral, Topical

4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

Lumbosacral Radicular Pain Management Market Innovation Trends Shaping Future Development

Companies operating within the lumbosacral radicular pain management market are concentrating on developing advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to provide a non-opioid alternative for prolonged pain relief. An investigational oral NaV1.8 pain signal inhibitor is an experimental drug targeting the NaV1.8 sodium channel, a key pathway for transmitting pain through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a US-based biotech company, announced the results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study met its primary endpoint, indicating a statistically significant and clinically meaningful reduction in pain from baseline within the suzetrigine group. Suzetrigine was generally well tolerated, with no serious adverse events reported. Vertex plans to address the significant placebo response in upcoming Phase 3 trials to better assess the drug’s efficacy.

Lumbosacral Radicular Pain Management Market Key Players Shaping Industry Direction

Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

View The Full Lumbosacral Radicular Pain Management Market Report:

https://thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lumbosacral Radicular Pain Management Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 13, 2026
Lumbosacral Radicular Pain Management Market Set To Expand From $1.17 Billion In 2026: Growth Outlook Through 2030

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Lumbosacral Radicular Pain Management Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The lumbosacral radicular pain management market has seen significant expansion over recent years. It is projected to expand from $0.9 billion in 2025 to $0.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to several factors including an increase in spinal disc disorders, the reliance on pharmacological methods for pain relief, the availability of hospital-based pain treatment, a rise in orthopedic consultations, and the development of physical therapy services.

The lumbosacral radicular pain management market size is anticipated to expand significantly over the next few years. It is projected to reach $1.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This growth during the forecast period is primarily driven by factors such as the expanding aging population, the increasing need for long-term pain management solutions, the adoption of non-invasive therapies, the growth of home-based rehabilitation services, and continuous advancements in pain diagnostics. Prominent trends for the forecast period encompass a growing inclination towards multimodal pain management approaches, a wider acceptance of non-opioid therapies, the expansion of interventions based on physical therapy, an increasing demand for minimally invasive pain treatments, and the integration of personalized pain management plans.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=94548638&type=smp&name=Lumbosacral%20Radicular%20Pain%20Management%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lumbosacral Radicular Pain Management Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The increasing occurrence of back pain conditions is projected to boost the expansion of the lumbosacral radicular pain management market in the future. Back pain disorders encompass various conditions impacting the spine, muscles, or nerves in the back, leading to discomfort or pain. The growing incidence of these disorders stems from sedentary lifestyles, which weaken back muscles, resulting in poor posture and chronic pain. Lumbosacral radicular pain management seeks to alleviate nerve root irritation in the lower back, thereby lessening pain and inflammation, while also restoring mobility and enhancing the quality of life. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, back problems were the third leading contributor to disease burden in Australia, representing 4.3% of the country’s total disease burden. Consequently, the increasing prevalence of back pain disorders fuels the growth of the lumbosacral radicular pain management market.

Lumbosacral Radicular Pain Management Market Segment Analysis And Revenue Potential

The lumbosacral radicular pain management market covered in this report is segmented –

1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

3) By Route Of Administration: Oral, Topical

4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

Lumbosacral Radicular Pain Management Market Innovation Trends Shaping Future Development

Companies operating within the lumbosacral radicular pain management market are concentrating on developing advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to provide a non-opioid alternative for prolonged pain relief. An investigational oral NaV1.8 pain signal inhibitor is an experimental drug targeting the NaV1.8 sodium channel, a key pathway for transmitting pain through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a US-based biotech company, announced the results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study met its primary endpoint, indicating a statistically significant and clinically meaningful reduction in pain from baseline within the suzetrigine group. Suzetrigine was generally well tolerated, with no serious adverse events reported. Vertex plans to address the significant placebo response in upcoming Phase 3 trials to better assess the drug’s efficacy.

Lumbosacral Radicular Pain Management Market Key Players Shaping Industry Direction

Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

View The Full Lumbosacral Radicular Pain Management Market Report:

https://thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lumbosacral Radicular Pain Management Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 13, 2026
Lumbosacral Radicular Pain Management Market Size Projected To Increase From $0.95 Billion To $1.17 Billion During The Forecast Period

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Lumbosacral Radicular Pain Management Market Growth From $0.95 Billion In 2026 To $1.17 Billion By 2030 At A CAGR Of 5.4%

The market for managing lumbosacral radicular pain has experienced notable expansion in recent times. Its valuation is projected to rise from $0.9 billion in 2025 to $0.95 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. Historical growth has been driven by factors such as an increasing prevalence of spinal disc issues, dependence on medication-based pain management, delivery of pain care within hospital settings, a higher number of orthopedic visits, and the expansion of physical therapy offerings.

The market for managing lumbosacral radicular pain is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $1.17 billion, reflecting a compound annual growth rate (CAGR) of 5.4%. This forecasted growth is driven by several key factors, including the rising number of elderly individuals, increased need for sustained pain relief, growing preference for non-invasive treatment options, broader use of home-based rehabilitation services, and continuous improvements in pain diagnostic technologies. Among the significant developments shaping the marketplace during this period are a heightened inclination toward multimodal pain management strategies, increased utilization of non-opioid medications, broader implementation of physical therapy-led interventions, stronger demand for procedures that are minimally invasive, and the integration of individualized pain management protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Lumbosacral Radicular Pain Management Market Growth Factors Supporting Long-Term Expansion

The anticipated expansion of the lumbosacral radicular pain management market is driven by the growing frequency of back pain disorders. These disorders encompass various conditions impacting the spine, back muscles, or nerves, resulting in discomfort or pain. This increase is largely attributed to sedentary lifestyles that weaken back muscles, leading to poor posture and ongoing pain. Management of lumbosacral radicular pain focuses on alleviating nerve root irritation in the lower back, thereby reducing pain and inflammation. It also helps restore mobility and enhances quality of life. A June 2024 report from the Australian Institute of Health and Welfare, an Australian government agency, indicated that in 2023, back problems ranked as the third leading cause of disease burden in Australia, accounting for 4.3% of the nation’s total disease burden. Thus, the rising incidence of back pain disorders fosters the growth of the lumbosacral radicular pain management market.

Lumbosacral Radicular Pain Management Market Categorization By Product Type And Application

The lumbosacral radicular pain management market covered in this report is segmented –

1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

3) By Route Of Administration: Oral, Topical

4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

Lumbosacral Radicular Pain Management Market Industry Trends Shaping Future Revenue Growth

Leading firms within the lumbosacral radicular pain management sector are prioritizing the development of innovative therapies, including experimental oral NaV1.8 pain signal inhibitors, to provide a non-opioid solution for sustained pain relief. This investigational oral NaV1.8 pain signal inhibitor is a medication currently under trial that targets the NaV1.8 sodium channel, a crucial mechanism for transmitting pain signals via sensory nerves. For example, in December 2024, Vertex Pharmaceuticals, a biotechnology company based in the US, disclosed findings from its Phase 2 trial of suzetrigine for treating painful lumbosacral radiculopathy (LSR). The trial achieved its main objective, demonstrating a statistically significant and clinically meaningful decrease in pain relative to baseline among those receiving suzetrigine. The drug was generally well tolerated, with no serious adverse effects being observed. Vertex intends to account for the high placebo response in upcoming Phase 3 studies to more accurately evaluate the treatment’s effectiveness.

Lumbosacral Radicular Pain Management Market Company Landscape And Strategic Competition

Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

Access The Complete Lumbosacral Radicular Pain Management Market Report:

https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Lumbosacral Radicular Pain Management Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 6, 2026
Facet-Joint Injection Market Expansion Is Reshaping Competitive Dynamics Across The Industry

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Facet-Joint Injection Market Growth From $3.17 Billion In 2026 To $4.1 Billion By 2030 At A CAGR Of 6.6%

The facet-joint injection market has seen notable expansion over the past few years. From a valuation of $2.97 billion in 2025, it is projected to climb to $3.18 billion by 2026, representing a compound annual growth rate (CAGR) of 6.9%. This upward trajectory during the historical timeframe was largely driven by factors such as the rising prevalence of spinal degeneration, higher rates of arthritis, growing awareness around pain management practices, the widespread application of corticosteroids, and an increase in the number of outpatient procedures.

Projections for the facet-joint injection market indicate robust expansion in the coming years. By 2030, its value is anticipated to reach $4.1 billion, reflecting a compound annual growth rate (CAGR) of 6.6%. This upward trajectory during the forecast timeframe is fueled by factors such as an aging demographic, a growing preference for minimally invasive treatments, the widespread occurrence of chronic pain, the broadening of ambulatory care services, and the utilization of imaging-guided interventions. Key developments shaping the forecast period include an escalating demand for low-invasive pain procedures, heightened application in treating chronic back pain, the proliferation of outpatient pain management centers, the integration of image-guided injection methodologies, and the increasing number of ambulatory surgical facilities.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Facet-Joint Injection Market Growth Momentum: Which Factors Are Influencing Demand?

The increasing occurrence of spinal disorders and chronic back ailments is anticipated to boost the expansion of the facet-joint injection market in the coming period. Spinal disorders and chronic back ailments describe prolonged conditions impacting the spine, including disc degeneration, arthritis, or nerve impingement, which result in ongoing pain, restricted movement, and a diminished quality of life. The growing frequency of spinal disorders and chronic back ailments stems from inactive lifestyles and poor posture habits, prompting individuals to pursue effective, minimally disruptive therapies that alleviate persistent pain and restore functional movement. Facet-joint injection aids spinal disorders and chronic back ailments by decreasing pain and swelling in the spine, offering relief to individuals affected by the rising issue of spinal conditions and chronic back pain. For example, in May 2023, based on data from Spinal Cord Inc., a US-based nonprofit resource center, approximately 18,000 new spinal cord injury (SCI) cases are documented each year in the United States, with around 302,000 people currently residing with spinal cord injuries across the nation. Thus, the increasing frequency of spinal disorders and chronic back ailments is fueling the advancement of the facet-joint injection market.

The escalating inclination toward minimally invasive techniques is anticipated to drive the growth of the facet-joint injection market in the future. Minimally invasive techniques denote medical procedures conducted via small incisions or without necessitating extensive surgical openings. The rise in minimally invasive techniques is fueled by patients’ growing desire for quicker recovery periods and lessened postoperative discomfort. Facet-joint injection improves minimally invasive techniques by delivering precise pain management and diagnostic clarity while avoiding major surgical involvement. For instance, in 2023, the American Society of Plastic Surgeons, a US-based specialty organization, reported that the overall count of minimally invasive cosmetic procedures increased from 23.7 million in 2022 to 25.4 million in 2023. Consequently, the rising demand for minimally invasive techniques is propelling the growth of the facet-joint injection market.

Facet-Joint Injection Market Categorization By Product Type And Application

The facet-joint injection market covered in this report is segmented –

1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

Facet-Joint Injection Market Trends Reshaping Industry Growth

Leading players in the facet-joint injection market are concentrating on creating advanced solutions, such as facet fusion systems, designed to deliver sustained pain relief and enhance therapeutic results. Facet fusion systems are specialized medical implants used to stabilize and unite the spine’s facet joints through the promotion of bone growth between adjacent vertebrae. A notable example occurred in March 2025, when Aurora Spine Corporation, a medical device firm based in the United States, secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its latest innovation—the AEROTM Facet Fusion System. This system employs a titanium plasma spray coating to facilitate better osseointegration and fusion capability. It accommodates a range of implant sizes to suit diverse patient anatomies and features radiolucent instrumentation that improves visibility during surgery. These attributes are collectively intended to boost procedural efficiency and long-term outcomes in addressing chronic back pain stemming from facet joint disorders.

Facet-Joint Injection Market Company Landscape And Strategic Competition

Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

Access The Complete Facet-Joint Injection Market Report:

https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Facet-Joint Injection Market Geographic Distribution And Regional Opportunities

North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 3, 2026
The Rising Prevalence Of Back Pain Disorders Is Fueling The Growth Of The Market Due To Increasing Sedentary Lifestyles And The Resulting Need For Effective Lumbosacral Radicular Pain Management Is Supporting Development Across The Lumbosacral Radicular Pain Management Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Lumbosacral Radicular Pain Management Market Progress Through 2030?

The lumbosacral radicular pain management market has experienced robust growth over recent years. Its valuation is projected to expand from $0.9 billion in 2025 to $0.95 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historical market expansion is attributable to several factors, including an increase in spinal disc disorder cases, the widespread use of pharmacological pain relief, hospital-based pain treatment options, a rise in orthopedic consultations, and the development of physical therapy services.

The lumbosacral radicular pain management market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $1.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This projected growth during the forecast period is driven by factors such as the increasing aging population, the escalating demand for long-term pain management, the wider adoption of non-invasive therapies, the expansion of home-based rehabilitation, and progress in pain diagnostics. Prominent trends for the forecast period involve a growing inclination towards multimodal pain management, the enhanced adoption of non-opioid therapies, an expansion of interventions based on physical therapy, a heightened demand for minimally invasive pain treatments, and the incorporation of personalized pain management plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp

What Primary Factors Are Fueling The Expansion Of The Lumbosacral Radicular Pain Management Market?

The increasing occurrence of back pain conditions is anticipated to stimulate the expansion of the lumbosacral radicular pain management market moving forward. Back pain disorders encompass a variety of ailments impacting the spine, muscles, or nerves in the back, leading to discomfort or pain. The rising incidence of back pain disorders is attributed to inactive lifestyles, which diminish back muscle strength, resulting in poor posture and persistent discomfort. Lumbosacral radicular pain management aims to alleviate nerve root irritation in the lower back, thereby reducing pain and inflammation. It also helps restore mobility and enhance the quality of life. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, back problems were the third leading contributor to disease burden in Australia in 2023, representing 4.3% of the country’s total disease burden. Consequently, the growing prevalence of back pain disorders is driving the growth of the lumbosacral radicular pain management market.

What Are The Major Segment Categories Within The Lumbosacral Radicular Pain Management Market?

The lumbosacral radicular pain management market covered in this report is segmented –

1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

3) By Route Of Administration: Oral, Topical

4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

What Trends Are Impacting The Lumbosacral Radicular Pain Management Market?

Leading companies within the lumbosacral radicular pain management market are concentrating on developing sophisticated treatments, such as investigational oral NaV1.8 pain signal inhibitors, to provide a non-opioid option for prolonged pain alleviation. An investigational oral NaV1.8 pain signal inhibitor represents a medication currently in the trial phase, designed to target the NaV1.8 sodium channel, a crucial pathway involved in pain transmission through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a biotech firm based in the US, released the outcomes from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study successfully achieved its primary goal, exhibiting a statistically significant and clinically relevant decrease in pain from baseline among participants receiving suzetrigine. Suzetrigine was generally well endured, with no severe adverse events documented. Vertex intends to tackle the significant placebo response in future Phase 3 trials to more effectively evaluate the drug’s effectiveness.

Who Are The Leading Firms Participating In The Lumbosacral Radicular Pain Management Market?

Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

Access The Complete Lumbosacral Radicular Pain Management Market Report:

https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report

Which Region Has The Strongest Presence In The Lumbosacral Radicular Pain Management Market?

North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lumbosacral Radicular Pain Management Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp

Browse Through More Reports Similar to the Global Lumbosacral Radicular Pain Management Market 2026, By The Business Research Company

Pain Management Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

Joint Pain Injections Market Report 2026

https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

Topical Pain Relief Market Report 2026

https://www.thebusinessresearchcompany.com/report/topical-pain-relief-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 20, 2026
Rising Prevalence Of Spinal Conditions Fueling The Growth Of The Market Due To Increasing Demand For Effective Pain Management Solutions Is Supporting Development Across The Facet-Joint Injection Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Facet-Joint Injection Market Change Between 2026 And 2030?

The facet-joint injection market has witnessed substantial growth in recent years. Its value is projected to expand from $2.97 billion in 2025 to $3.18 billion in 2026, at a compound annual growth rate (CAGR) of 6.9%. This historical growth can be attributed to the prevalence of spinal degeneration, the incidence of arthritis, heightened awareness of pain management, the use of corticosteroids, and the increase in outpatient procedures.

The facet-joint injection market size is anticipated to undergo robust expansion in the coming years. This market is forecast to achieve a valuation of $4.1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. The upward trend during the projected period stems from the aging population, a preference for minimally invasive treatments, the prevalence of chronic pain, the growth of ambulatory care, and the use of imaging-guided procedures. Noteworthy trends for the forecast period encompass an increasing need for minimally invasive pain interventions, broader application in managing chronic back pain, the rise of outpatient pain clinics, the embrace of image-guided injection methods, and the expansion of ambulatory surgical centers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

What Are The Main Drivers Accelerating The Growth Of The Facet-Joint Injection Market?

The facet-joint injection market is projected to expand due to the increasing incidence of spinal conditions and persistent back discomfort. These issues encompass chronic ailments affecting the spine, such as disc degeneration, arthritis, or nerve compression, which lead to ongoing pain, restricted movement, and a diminished quality of life. The growing occurrence of spinal diseases and chronic back pain results from inactive lifestyles and poor posture habits, prompting individuals to seek effective, low-disruption treatments that alleviate persistent discomfort and restore functional movement. Facet-joint injections provide relief for those suffering from spinal diseases and chronic back pain by reducing inflammation and pain in the spine. For instance, in May 2023, according to Spinal Cord Inc., a US-based non-profit resource center, in 2023, around 18,000 new spinal cord injury (SCI) cases are reported annually in the United States, with an estimated 302,000 individuals currently living with spinal cord injuries nationwide. Consequently, the rising prevalence of spinal diseases and chronic back pain is driving the growth of the facet-joint injection market.

What Are The Core Segment Classifications In The Facet-Joint Injection Market?

The facet-joint injection market covered in this report is segmented –

1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

Which Trends Are Expected To Shape The Facet-Joint Injection Market?

Leading companies in the facet-joint injection market are concentrating on developing innovative products, such as facet fusion systems, to deliver more prolonged relief and enhance treatment outcomes. Facet fusion systems are medical devices specifically designed to stabilize and fuse the facet joints of the spine by promoting bone growth between neighboring vertebrae. For example, in March 2025, Aurora Spine Corporation, a medical device company based in the US, declared that its newest product, the AEROTM Facet Fusion System, had achieved 510(k) clearance from the U.S. Food and Drug Administration (FDA). This system incorporates a titanium plasma spray coating to improve osseointegration and fusion potential. It also supports multiple implant sizes to suit varied patient anatomies and features radiolucent instrumentation to improve intraoperative visibility. These combined features aim to boost procedural efficiency and achieve better long-term results in treating chronic back pain caused by facet joint disorders.

Which Industry Players Are Present In The Facet-Joint Injection Market?

Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

Access The Complete Facet-Joint Injection Market Report:

https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

Which Region Has The Strongest Presence In The Facet-Joint Injection Market?

North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Facet-Joint Injection Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2026, By The Business Research Company

Self Injections Market Report 2026

https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

Joint Pain Injections Market Report 2026

https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

Facial Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 19, 2026
Global Lumbosacral Radicular Pain Management Market Analysis For 2026–2030 With Strategic Insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Lumbosacral Radicular Pain Management Market Progress Between 2026 And 2030?

The lumbosacral radicular pain management market has experienced robust growth in recent times. Projections indicate its expansion from $0.9 billion in 2025 to $0.95 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. Historically, this growth is attributable to factors such as the increasing incidence of spinal disc disorders, the common use of pharmacological solutions for pain relief, widespread hospital-based pain treatment options, a rise in orthopedic consultations, and the expansion of physical therapy services.

The lumbosacral radicular pain management market size is anticipated to undergo substantial growth over the coming years. It is forecasted to reach $1.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.4%. This expansion during the projection period stems from factors such as an aging population, the escalating need for long-term pain solutions, the increasing embrace of non-invasive treatments, the proliferation of home-based rehabilitation, and breakthroughs in pain diagnostics. Key trends influencing the forecast period include a heightened preference for multimodal pain management, a greater adoption of non-opioid therapies, an enlargement of physical therapy-driven interventions, a surging demand for minimally invasive pain procedures, and the integration of customized pain management plans.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp

Which Drivers Are Supporting The Lumbosacral Radicular Pain Management Market Growth?

The increasing occurrence of back pain conditions is anticipated to drive the expansion of the lumbosacral radicular pain management market moving forward. Back pain disorders encompass various ailments impacting the spine, muscles, or nerves of the back, leading to unease or pain. The growing incidence of these disorders is attributed to inactive lifestyles that contribute to weakened back muscles, resulting in poor posture and chronic discomfort. Lumbosacral radicular pain management focuses on alleviating nerve root irritation in the lower back, thereby diminishing pain and swelling. This approach also helps restore physical movement and enhance one’s overall well-being. For example, in June 2024, data from the Australian Institute of Health and Welfare, a government body based in Australia, revealed that in 2023, back problems were the third leading contributor to disease burden in Australia, accounting for 4.3% of the country’s total disease burden. Consequently, the increasing occurrence of back pain conditions stimulates the growth of the lumbosacral radicular pain management market.

How Are Different Segments Classified In The Lumbosacral Radicular Pain Management Market Segment Analysis?

The lumbosacral radicular pain management market covered in this report is segmented –

1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

3) By Route Of Administration: Oral, Topical

4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

Which Trends Are Shaping Growth In The Lumbosacral Radicular Pain Management Market?

Leading companies in the lumbosacral radicular pain management market are concentrating on developing advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to offer a non-opioid alternative for long-lasting pain relief. An investigational oral NaV1.8 pain signal inhibitor is a trial-stage medication designed to target the NaV1.8 sodium channel, a key pathway for transmitting pain through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a US-based biotech company, announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pain from baseline in the suzetrigine group. Suzetrigine was generally well tolerated, with no serious adverse events reported. Vertex plans to address the high placebo response in future Phase 3 trials to better assess the drug’s efficacy.

Who Are The Companies Driving Activity In The Lumbosacral Radicular Pain Management Market?

Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

Get The Full Lumbosacral Radicular Pain Management Market Report:

https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report

Which Region Is The Leading Market For The Lumbosacral Radicular Pain Management Market?

North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lumbosacral Radicular Pain Management Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report

Browse Through More Reports Similar to the Global Lumbosacral Radicular Pain Management Market 2026, By The Business Research Company

Pain Management Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

Joint Pain Injections Market Report 2026

https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

Topical Pain Relief Market Report 2026

https://www.thebusinessresearchcompany.com/report/topical-pain-relief-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 1, 2026
Facet-Joint Injection Market Forecast Showing Industry Progress And Growth Trends

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Facet-Joint Injection Market Progress Between 2026 And 2030?

The market for facet-joint injections has experienced significant expansion recently. This market is projected to expand from $2.97 billion in 2025 to reach $3.18 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.9%. Historically, this growth can be attributed to factors such as the prevalence of spinal degeneration, the incidence of arthritis, increased awareness of pain management techniques, the utilization of corticosteroids, and the rise in outpatient procedures.

The facet-joint injection market size is anticipated to experience robust expansion over the coming years. It is projected to reach $4.1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is driven by factors such as an aging population, a preference for minimally invasive treatments, the widespread occurrence of chronic pain, the growth of ambulatory care, and the use of imaging-guided procedures. Key developments expected in this period include an increasing need for minimally invasive pain interventions, greater application in managing chronic back pain, the proliferation of outpatient pain clinics, the adoption of image-guided injection methods, and the broadening of ambulatory surgical centers.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

What Primary Drivers Are Shaping The Facet-Joint Injection Market?

The increasing occurrence of spinal diseases and persistent back pain is anticipated to fuel the expansion of the facet-joint injection market in the coming years. These conditions encompass long-standing ailments impacting the spine, such as disc degeneration, arthritis, or nerve compression, which result in continuous discomfort, restricted movement, and a diminished quality of life. The surge in spinal diseases and chronic back pain can be attributed to inactive lifestyles and improper posture, prompting individuals to seek efficacious, minimally disruptive treatments to alleviate ongoing discomfort and restore functional movement. Facet-joint injection offers relief for spinal diseases and chronic back pain by diminishing spinal pain and inflammation. For instance, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, reported approximately 18,000 new spinal cord injury (SCI) cases annually in the United States in 2023, with an estimated 302,000 individuals presently living with spinal cord injuries nationwide. Consequently, the growing prevalence of spinal diseases and chronic back pain is a significant factor propelling the facet-joint injection market’s growth.

What Are The Main Segments Within The Facet-Joint Injection Market Segment Structure?

The facet-joint injection market covered in this report is segmented –

1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

What Trends Are Affecting The Growth Of The Facet-Joint Injection Market?

Major companies operating in the facet-joint injection market are concentrating their efforts on developing innovative offerings, such as facet fusion systems, to provide more enduring relief and enhance therapeutic results. Facet fusion systems are defined as medical devices engineered to stabilize and join the spine’s facet joints by encouraging bone development between adjacent vertebrae. As an illustration, in March 2025, Aurora Spine Corporation, a US-based medical device company, announced that the AEROTM Facet Fusion System, its newest product, had secured 510(k) clearance from the U.S. Food and Drug Administration (FDA). This system incorporates a titanium plasma spray coating to boost osseointegration and its capacity for fusion. Furthermore, it supports various implant sizes to suit diverse patient anatomies and includes radiolucent instrumentation to improve visibility during operations. These combined attributes are intended to enhance the effectiveness of procedures and the long-term prognosis for individuals suffering from chronic back pain originating from facet joint disorders.

Who Are The Companies Participating In The Facet-Joint Injection Market?

Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

Get The Full Facet-Joint Injection Market Report:

https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

Which Region Is The Leading Market For The Facet-Joint Injection Market?

North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Facet-Joint Injection Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2026, By The Business Research Company

Self Injections Market Report 2026

https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

Joint Pain Injections Market Report 2026

https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

Facial Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

April 30, 2026